Search results
Showing 331 to 345 of 8314 results
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
This guideline covers when to offer and discuss caesarean birth, procedural aspects of the operation, and care after caesarean birth. It aims to improve the consistency and quality of care for women and pregnant people who are thinking about having a caesarean birth or have had a caesarean birth in the past and are now pregnant again.
Neonatal infection: antibiotics for prevention and treatment (NG195)
This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.
This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.
Hyperparathyroidism (primary): diagnosis, assessment and initial management (NG132)
This guideline covers diagnosing, assessing and managing primary hyperparathyroidism. It aims to improve recognition and treatment of this condition, reducing long-term complications and improving quality of life.
This guideline covers the rapid identification and early management of major trauma in pre-hospital and hospital settings, including ambulance services, emergency departments, major trauma centres and trauma units. It aims to reduce deaths and disabilities in people with serious injuries by improving the quality of their immediate care. It does not cover care for people with burns.
This guideline covers the routine antenatal care that women and their babies should receive. It aims to ensure that pregnant women are offered regular check-ups, information and support.
In development Reference number: GID-TA11495 Expected publication date: 07 January 2026
Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]
In development Reference number: GID-TA11587 Expected publication date: 08 January 2026
All NICE products on brain cancers. Includes any guidance, advice and quality standards.
All NICE products on ovarian cancer. Includes any guidance, advice and quality standards.
All NICE products on genomic biomarker-based cancer treatments. Includes any guidance.
All NICE products on lung cancer. Includes any guidance, advice and quality standards.
All NICE products on metastases. Includes any guidance, advice and quality standards.
All NICE products on liver cancers. Includes any guidance.